Anamorelin hydrochloride is under clinical development by Helsinn Healthcare and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Anamorelin hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anamorelin hydrochloride overview
Anamorelin hydrochloride (RC-1291, ONO-7643) is under development for the treatment of cancer cachexia/anorexia in non-small cell lung cancer (NSCLC) patients, weight loss in CKD and cancer-related fatigue. It is a new molecular entity which is formulated as a tablet and is administered through oral route. The drug candidate acts by targeting the ghrelin receptor.
Helsinn Healthcare overview
Helsinn Healthcare, a subsidiary of 3B Future Holding SA, is a pharmaceutical company that provides therapies for cancer and chronic diseases.
For a complete picture of Anamorelin hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
